Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide and Metronomic Temozolomide in Pediatric HGG/DIPG
NCT01517776Phase 2Terminated
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jan 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cilengitide in high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), sponsored by Martin Luther University Halle-Wittenberg. Started Jan 2012; status: terminated.
02
Drugs
cilengitide
03
Conditions
high-grade glioma (HGG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT01517776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01517776.